Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Arrowhead Pharmaceuticals (ARWR) Shares Issued (2016 - 2025)

Historic Shares Issued for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Q4 2025 value amounting to $46.8 million.

  • Arrowhead Pharmaceuticals' Shares Issued rose 8732.8% to $46.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $263.2 million, marking a year-over-year decrease of 4202.18%. This contributed to the annual value of $241.4 million for FY2025, which is 4376.71% down from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Shares Issued stood at $46.8 million for Q4 2025, which was up 8732.8% from $216.4 million recorded in Q1 2025.
  • Arrowhead Pharmaceuticals' Shares Issued's 5-year high stood at $429.0 million during Q1 2024, with a 5-year trough of $267000.0 in Q4 2023.
  • In the last 5 years, Arrowhead Pharmaceuticals' Shares Issued had a median value of $1.9 million in 2021 and averaged $52.4 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Shares Issued crashed by 9798.11% in 2023 and then skyrocketed by 8239961.54% in 2024.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Shares Issued stood at $1.9 million in 2021, then crashed by 69.44% to $576000.0 in 2022, then crashed by 53.65% to $267000.0 in 2023, then skyrocketed by 9263.3% to $25.0 million in 2024, then soared by 87.33% to $46.8 million in 2025.
  • Its Shares Issued stands at $46.8 million for Q4 2025, versus $216.4 million for Q1 2025 and $25.0 million for Q4 2024.